Free Delivery on all orders over £39 *Exclusions Apply*

Product image

Mirataz 20mg/g Transdermal Ointment for Cats


Mirataz 20mg/g Transdermal ointment for cats is used for body weight gain in cats experiencing poor appetite and weight loss resulting from chronic medical conditions.

Legal Category : POM-V

A valid veterinary prescription is required for purchase of this product.

Read More

Upload Prescriptions

  • Prescription *

    Please upload your prescription for this product.Max file size: 25 MBPermitted file types: jpg jpeg jpe png gif pdf

Product total

Options total

Grand total

View POM


All orders over £39 receive free delivery * *terms and conditions apply


Returns It should be noted that, unfortunately, we cannot accept returns of any labelled products, including prescription medicines and flea and worming products. If the customer has requested a cancellation but the order has already been dispatched then we will not be able to cancel and refund the order. This also applies if the customer has ordered the incorrect dosage. Returns of any labelled products are only acceptable if it is due to an error in processing, or for an official recall. We are also unable to accept the returns of Caninsulin syringes, even if the packaging is unopened.

View More


Mirataz 20mg/g Transdermal Ointment

The active ingredient Mirtazapine is absorbed through the skin of the ear into the bloodstream. The effects of mirtazapine on weight gain are complex and not fully understood. They include blocking some of the actions of serotonin and histamine, substances involved in the regulation of appetite, and an effect on levels of leptin, a hormone that controls hunger.

Use this product as directed by your veterinary surgeon. You should carefully read all product packaging and labels prior to use.


The importance of treating poor appetite and weight loss resulting from chronic medical conditions in cats

Unintended feline weight loss may be associated with serious consequences;

  •   A Low Body Condition Score (BCS) is linked to reduced survival across many disease states
  •   Prolonged inadequate nutrition may be more detrimental to the patient than the primary disease process5
  •   In diseased cats a change in production of inflammatory cytokines, catecholamines, cortisol, insulin and glucagon can trigger a hyper-metabolic state, characterised by protein catabolism, cachexia, insulin resistance, lipolysis and increased energy expenditure
  •   Patients with cachexia may get into a negative nitrogen and energy balance, lose lean body mass and are at risk of developing malnutrition. Malnutrition can result in anaemia, hypoproteinaemia and reduced immune function, wound healing and organ function
  •   Poor appetite is emotionally distressing to owners and is perceived as an indication of poor quality-of-life

Mirataz is the first licensed veterinary medicinal product for body weight gain in cats experiencing poor appetite.

The active ingredient, mirtazapine, addresses reduced appetite and induces significant weight gain in as little as 14 days.

This can allow for a swift response to initial symptoms – improving condition and wellbeing before you have a definitive diagnosis, alongside providing support to patients already receiving long term treatment.